Novel approaches for immunotherapeutic intervention in Alzheimer's disease

Neurochemistry International

Volumn 49, Issue 2, 2006, Pages 113-126

  Vasilevko, Vitaly ^a   Cribbs, David H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloid; Adenovirus vector; Amyloid precursor protein; AN1792; Complement; Immunotherapy; Mesenchymal stem cells; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; GLATIRAMER; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; M 266 MONOCLONAL ANTIBODY; MINOCYCLINE; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR; POLYSORBATE 80; QS 21; QUIL A; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY TITER; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; COGNITION; COMPLEMENT ACTIVATION; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENCEPHALITIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; INFLAMMATION; MENINGOENCEPHALITIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; VIRAL GENE DELIVERY SYSTEM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; ENCEPHALITIS; GENETIC VECTORS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; INTRACRANIAL HEMORRHAGES; METABOLIC CLEARANCE RATE; TREATMENT FAILURE;

MUS MUSCULUS;

EID: 33746859735     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2006.03.019     Document Type: Article

References (143)

1. Afagh A., Cummings B.J., Cribbs D.H., Cotman C.W., and Tenner A.J. Localization and cell association of C1q in Alzheimer's disease brain. Exp. Neurol. 138 (1996) 22-32
2. Akiyama H., and McGeer P.L. Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat. Med. 10 (2004) 117-118 (author reply 118-119)
3. Askanas V., Alvarez R.B., and Engel W.K. beta-Amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann. Neurol. 34 (1993) 551-560
4. Bacskai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P., Schenk D., and Hyman B.T. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7 (2001) 369-372
5. Bacskai B.J., Kajdasz S.T., McLellan M.E., Games D., Seubert P., Schenk D., and Hyman B.T. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 22 (2002) 7873-7878
6. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., and Yednock T. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 2023-2028
7. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 (2000) 916-919
8. Barry F.P., Murphy J.M., English K., and Mahon B.P. Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev. 14 (2005) 252-265
9. Bartlett J.S., Wilcher R., and Samulski R.J. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74 (2000) 2777-2785
10. Bayer A.J., Bullock R., Jones R.W., Wilkinson D., Paterson K.R., Jenkins L., Millais S.B., and Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64 (2005) 94-101
11. Bessis N., GarciaCozar F.J., and Boissier M.C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 11 Suppl. 1 (2004) S10-S17
12. Billings L.M., Oddo S., Green K.N., McGaugh J.L., and Laferla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 (2005) 675-688
13. Birmingham K., and Frantz S. Set back Alzheimer vaccine studies. Nat. Med. 8 (2002) 199-200
14. Blanco Y., Saiz A., Carreras E., and Graus F. Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. Lancet Neurol. 4 (2005) 54-63
15. Blattman J.N., and Greenberg P.D. Cancer immunotherapy: a treatment for the masses. Science 305 (2004) 200-205
16. Bowers W.J., Olschowka J.A., and Federoff H.J. Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy. Gene Ther. 10 (2003) 941-945
17. Brazil M.I., Chung H., and Maxfield F.R. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. J. Biol. Chem. 275 (2000) 16941-16947
18. Brendza R.P., Bacskai B.J., Cirrito J.R., Simmons K.A., Skoch J.M., Klunk W.E., Mathis C.A., Bales K.R., Paul S.M., Hyman B.T., and Holtzman D.M. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest. 115 (2005) 428-433
19. Burt R.K., Verda L., Statkute L., Quigley K., Yaung K., Brush M., and Oyama Y. Stem cell transplantation for autoimmune diseases. Clin. Adv. Hematol. Oncol. 2 (2004) 313-319
20. Cai J., Wang S., Zhong Y., Cheng J., Ji Z., Sheng S., and Zhang C. Screening and characterization of human single-chain Fv antibody against beta-amyloid peptide 40. Neuroreport 14 (2003) 265-268
21. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., and Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8 (2005) 79-84
22. Cooper N.R., Bradt B.M., O'Barr S., and Yu J.X. Focal inflammation in the brain: role in Alzheimer's disease. Immunol. Res. 21 (2000) 159-165
23. Cribbs D.H., Ghochikyan A., Tran M., Vasilevko V., Petrushina I., Sadzikava N., Kesslak P., Kieber-Emmons T., Cotman C.W., and Agadjanyan M.G. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 15 (2003) 505-514
24. Cuello A.C. Intracellular and extracellular Abeta, a tale of two neuropathologies. Brain Pathol. 15 (2005) 66-71
25. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur. J. Pharmacol. 500 (2004) 399-411
26. Das P., Murphy M.P., Younkin L.H., Younkin S.G., and Golde T.E. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging 22 (2001) 721-727
27. de Buys P., Khanna D., and Furst D.E. Hemopoietic stem cell transplantation in rheumatic diseases-an update. Autoimmun. Rev. 4 (2005) 442-449
28. Deane R., Wu Z., Sagare A., Davis J., Du Yan S., Hamm K., Xu F., Parisi M., LaRue B., Hu H.W., Spijkers P., Guo H., Song X., Lenting P.J., Van Nostrand W.E., and Zlokovic B.V. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43 (2004) 333-344
29. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 8850-8855
30. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., and Holtzman D.M. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295 (2002) 2264-2267
31. DeMattos R.B., Bales K.R., Parsadanian M., O'Dell M.A., Foss E.M., Paul S.M., and Holtzman D.M. Plaque-associated disruption of CSF and plasma amyloid-b (Ab) equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 81 (2002) 229-236
32. DeMattos R.B., Boone L.I., Hepburn D.L., Parsadanian M., Bryan M.T., Ness D.K., Piroozi K.S., Holtzman D.M., Bales K.R., Gitter B.D., Paul S.M., and Racke M. In vitro and in vivo characterization of beta-amyloid antibodies binding to cerebral amyloid angiopathy (CAA) and the selective exacerbation of CAA-associated microhemorrhage. Neurobiol. Aging 25 (2004) 577
33. DiCarlo G., Wilcock D., Henderson D., Gordon M., and Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP + PS1 transgenic mice. Neurobiol. Aging 22 (2001) 1007-1012
34. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., and Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5 (2002) 452-457
35. Eikelenboom P., and Stam F.C. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. 57 (1982) 239-242
36. Eikelenboom P., and Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. Aging 17 (1996) 673-680
37. Eikelenboom P., Zhan S.S., van Gool W.A., and Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci. 15 (1994) 447-450
38. Esler W.P., and Wolfe M.S. A portrait of Alzheimer secretases-new features and familiar faces. Science 293 (2001) 1449-1454
39. Ferrer I., Rovira M.B., Guerra M.L.S., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14 (2004) 11-20
40. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., and Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64 (2005) 1563-1572
41. Frenkel D., Maron R., Burt D.S., and Weiner H.L. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest. 115 (2005) 2423-2433
42. Gerdes C.A., Castro M.G., and Lowenstein P.R. Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. Mol. Ther. 2 (2000) 330-338
43. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., and Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
44. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., and Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 10417-10422
45. Gouras G.K., Almeida C.G., and Takahashi R.H. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol. Aging 26 9 (2005) 1235-1244
46. Gouras G.K., Tsai J., Naslund J., Vincent B., Edgar M., Checler F., Greenfield J.P., Haroutunian V., Buxbaum J.D., Xu H., Greengard P., and Relkin N.R. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 156 (2000) 15-20
47. Gregory C.A., Prockop D.J., and Spees J.L. Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation. Exp. Cell Res. 306 (2005) 330-335
48. Grubeck-Loebenstein B., and Wick G. The aging of the immune system. Adv. Immunol. 80 (2002) 243-284
49. Gyure K.A., Durham R., Stewart W.F., Smialek J.E., and Troncoso J.C. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch. Pathol. Lab. Med. 125 (2001) 489-492
50. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
51. Hardy J.A., and Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256 (1992) 184-185
52. Hartman R.E., Izumi Y., Bales K.R., Paul S.M., Wozniak D.F., and Holtzman D.M. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J. Neurosci. 25 (2005) 6213-6220
53. Head E., Azizeh B.Y., Lott I.T., Tenner A.J., Cotman C.W., and Cribbs D.H. Complement association with neurons and B-amyloid deposition in the brains of aged individuals with Down syndrome. Neurobiol. Dis. 8 (2001) 252-265
54. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., and Nitsch R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
55. Holmes C., El-Okl M., Williams A.L., Cunningham C., Wilcockson D., and Perry V.H. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74 (2003) 788-789
56. Holtzman D.M., Bales K.R., Paul S.M., and DeMattos R.B. Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Adv. Drug Deliv. Rev. 54 (2002) 1603-1613
57. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., and Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
58. Jayne D., and Tyndall A. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13 (2004) 359-365
59. Ji J.F., He B.P., Dheen S.T., and Tay S.S. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells 22 (2004) 415-427
60. Jiang H., Burdick D., Glabe C.G., Cotman C.W., and Tenner A.J. beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152 (1994) 5050-5059
61. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
62. Klein W.L., Krafft G.A., and Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 24 (2001) 219-224
63. Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V., Spooner E.T., Jiang L., Anwyl R., Selkoe D.J., and Rowan M.J. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11 (2005) 556-561
64. Kochanek S., Clemens P.R., Mitani K., Chen H.H., Chan S., and Caskey C.T. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 5731-5736
65. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Younkin S., and Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22 (2002) 6331-6335
66. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 6448-6453
67. Lee M., Bard F., Johnson-Wood K., Lee C., Hu K., Griffith S.G., Black R.S., Schenk D., and Seubert P. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann. Neurol. 58 (2005) 430-435
68. Lemere C., Spooner E.T., LaFrancois J., Malester B., Mori C., Leverone J.F., Matsuoka Y., Taylor J.W., DeMattos R.B., Holtzman D.M., Clements J.D., Selkoe D.J., and Duff K. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol. Dis. 14 1 (2003) 10-18
69. Liu R., Yuan B., Emadi S., Zameer A., Schulz P., McAllister C., Lyubchenko Y., Goud G., and Sierks M.R. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 43 (2004) 6959-6967
70. Loo D.T., Copani A., Pike C.J., Whittemore E.R., Walencewicz A.J., and Cotman C.W. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 7951-7955
71. Lorenzo A., and Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 12243-12247
72. Maggio J.E., Stimson E.R., Ghilardi J.R., Allen C.J., Dahl C.E., Whitcomb D.C., Vigna S.R., Vinters H.V., Labenski M.E., and Mantyh P.W. Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 5462-5466
73. Maione D., Della Rocca C., Giannetti P., D'Arrigo R., Liberatoscioli L., Franlin L.L., Sandig V., Ciliberto G., La Monica N., and Savino R. An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 5986-5991
74. Maione D., Wiznerowicz M., Delmastro P., Cortese R., Ciliberto G., La Monica N., and Savino R. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum. Gene Ther. 11 (2000) 859-868
75. Manoutcharian K., Acero G., Munguia M.E., Becerril B., Massieu L., Govezensky T., Ortiz E., Marks J.D., Cao C., Ugen K., and Gevorkian G. Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42. Neurobiol. Dis. 17 (2004) 114-121
76. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., and Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64 (2005) 129-131
77. Mochizuki A., Tamaoka A., Shimohata A., Komatsuzaki Y., and Shoji S. Abeta42-positive non-pyramidal neurons around amyloid plaques in Alzheimer's disease. Lancet 355 (2000) 42-43
78. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
79. Morgan D., Gordon M.N., Tan J., Wilcock D., and Rojiani A.M. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J. Neuropathol. Exp. Neurol. 64 (2005) 743-753
80. Mori C., Spooner E.T., Wisniewsk K.E., Wisniewski T.M., Yamaguch H., Saido T.C., Tolan D.R., Selkoe D.J., and Lemere C.A. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 9 (2002) 88-102
81. Murphy Jr. G.M., Forno L.S., Higgins L., Scardina J.M., Eng L.F., and Cordell B. Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders. Am. J. Pathol. 144 (1994) 1082-1088
82. Muruve D.A. The innate immune response to adenovirus vectors. Hum. Gene Ther. 15 (2004) 1157-1166
83. Nakagawa Y., Nakammura M., McIntosh T.K., Rodriguez A., Berlin J.A., Smith D.H., Saatman K.E., Raghupathi R., Clemens J., Saido T.C., Schmidt M.L., Lee V.M., and Trojanowski J.Q. Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Abeta deposition during aging. J. Comp. Neurol. 411 (1999) 390-398
84. Nakagawa Y., Reed L., Nakamura M., McIntosh T.K., Smith D.H., Saatman K.E., Raghupathi R., Clemens J., Saido T.C., Lee V.M., and Trojanowski J.Q. Brain trauma in aged transgenic mice induces regression of established abeta deposits. Exp. Neurol. 163 (2000) 244-252
85. Nguyen M.D., Julien J.P., and Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration?. Nat. Rev. Neurosci. 3 (2002) 216-227
86. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9 (2003) 448-452
87. Nicoll J.A., Yamada M., Frackowiak J., Mazur-Kolecka B., and Weller R.O. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol. Aging 25 (2004) 589-597 (discussion 603-584)
88. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., and LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 (2004) 321-332
89. Oddo S., Caccamo A., Smith I.F., Green K.N., and LaFerla F.M. A dynamic relationship between intracellular and extracellular pools of Abeta. Am. J. Pathol. 168 (2006) 184-194
90. Olschowka J.A., Bowers W.J., Hurley S.D., Mastrangelo M.A., and Federoff H.J. Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Mol. Ther. 7 (2003) 218-227
91. Orgogozo J.M., Gilman S., Dartigues J.M., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., and Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 1 (2003) 46-54
92. Paresce D.M., Ghosh R.N., and Maxfield F.R. Microglial cells internalize aggregates of the Alzheimer's disease amyloid β-protein via a scavenger receptor. Neuron 17 (1996) 553-565
93. Parks R.J., Chen L., Anton M., Sankar U., Rudnicki M.A., and Graham F.L. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 13565-13570
94. Perry G., Cras P., Siedlak S.L., Tabaton M., and Kawai M. β protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer's disease. Am. J. Pathol. 140 2 (1992) 283-290
95. Perry V.H., Newman T.A., and Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat. Rev. Neurosci. 4 (2003) 103-112
96. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., and Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298 (2002) 1379
97. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., and Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13 (1993) 1676-1687
98. Pike C.J., Walencewicz A.J., Glabe C.G., and Cotman C.W. Aggregation-related toxicity of synthetic β-amyloid protein in hippocampal cultures. Eur. J. Pharm. 207 (1991) 367-368
99. Pike C.J., Walencewicz A.J., Glabe C.G., and Cotman C.W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563 (1991) 311-314
100. Price D.L., and Sisodia S.S. Cellular and molecular biology of Alzheimer's disease and animal models. Annu. Rev. Med. 45 (1994) 435-446
101. Quinn J., Montine T., Morrow J., Woodward W.R., Kulhanek D., and Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J. Neuroimmunol. 137 (2003) 32-41
102. Racke M.M., Boone L.I., Hepburn D.L., Parsadainian M., Bryan M.T., Ness D.K., Piroozi K.S., Jordan W.H., Brown D.D., Hoffman W.P., Holtzman D.M., Bales K.R., Gitter B.D., May P.C., Paul S.M., and DeMattos R.B. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25 (2005) 629-636
103. Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D., Civin W.H., Brachova L., Bradt B., Ward P., et al. Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10016-10020
104. Ryan J.M., Barry F.P., Murphy J.M., and Mahon B.P. Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm. (Lond.) 2 (2005) 8
105. Schenk D. Opinion: amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3 (2002) 824-828
106. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments]. Nature 400 (1999) 173-177
107. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 6 (1991) 487-498
108. Selkoe D.J. Alzheimer's disease: a central role for amyloid. J. Neuropath. Exp. Neurol. 53 (1994) 438-447
109. Selkoe D.J. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell Biol. 10 (1994) 373-403
110. Selkoe D.J., and Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 545-584
111. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 1 (2002) 3
112. Sheng J.G., Bora S.H., Xu G., Borchelt D.R., Price D.L., and Koliatsos V.E. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPs we transgenic mice. Neurobiol. Dis. 14 (2003) 133-145
113. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., and Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106 (2000) 1489-1499
114. Sisodia S.S., and Price D.L. Role of the beta-amyloid protein in Alzheimer's disease. FASEB J. 9 (1995) 366-370
115. Smith D.H., Chen X.H., Nonaka M., Trojanowski J.Q., Lee V.M., Saatman K.E., Leoni M.J., Xu B.N., Wolf J.A., and Meaney D.F. Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. J. Neuropathol. Exp. Neurol. 58 (1999) 982-992
116. Steinberg D. Companies halt first Alzheimer's vaccine trial. Scientist (2002) 22-23
117. Takahashi R.H., Almeida C.G., Kearney P.F., Yu F., Lin M.T., Milner T.A., and Gouras G.K. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24 (2004) 3592-3599
118. Tammer A.H., Coia G., Cappai R., Fuller S., Masters C.L., Hudson P., and Underwood J.R. Generation of a recombinant Fab antibody reactive with the Alzheimer's disease-related Abeta peptide. Clin. Exp. Immunol. 129 (2002) 453-463
119. Tenner A.J. Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol. Aging 22 (2001) 849-861
120. Thomas C.E., Schiedner G., Kochanek S., Castro M.G., and Lowenstein P.R. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7482-7487
121. Thomas C.E., Schiedner G., Kochanek S., Castro M.G., and Lowenstein P.R. Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum. Gene Ther. 12 (2001) 839-846
122. Troeger A., Meisel R., Moritz T., and Dilloo D. Immunotherapy in allogeneic hematopoietic stem cell transplantation-not just a case for effector cells. Bone Marrow Transplant. 35 Suppl. 1 (2005) S59-S64
123. Tseng B.P., Esler W.P., Clish C.B., Stimson E.R., Ghilardi J.R., Vinters H.V., Mantyh P.W., Lee J.P., and Maggio J.E. Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. Biochemistry 38 (1999) 10424-10431
124. Tseng B.P., Kitazawa M., and LaFerla F.M. Amyloid beta-peptide: the inside story. Curr. Alzheimer Res. 1 (2004) 231-239
125. Tuszynski M.H., Thal L., Pay M., Salmon D.P., U H.S., Bakay R., Patel P., Blesch A., Vahlsing H.L., Ho G., Tong G., Potkin S.G., Fallon J., Hansen L., Mufson E.J., Kordower J.H., Gall C., and Conner J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11 (2005) 551-555
126. Uryu K., Laurer H., McIntosh T., Pratico D., Martinez D., Leight S., Lee V.M., and Trojanowski J.Q. Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J. Neurosci. 22 (2002) 446-454
127. Verbeek M.M., Otte-Holler I., Veerhuis R., Ruiter D.J., and De Waal R.M. Distribution of A beta-associated proteins in cerebrovascular amyloid of Alzheimer's disease. Acta Neuropathol. (Berl.) 96 (1998) 628-636
128. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amylolid β protein potently inhibit hipocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
129. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
130. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., and Trommer B.L. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924 (2002) 133-140
131. Webster S.D., Galvan M.D., Ferran E., Garzon-Rodriguez W., Glabe C.G., and Tenner A.J. Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J. Immunol. 166 (2001) 7496-7503
132. Webster S.D., Tenner A.J., Poulos T.L., and Cribbs D.H. The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation. Neurobiol. Aging 20 (1999) 297-304
133. Webster S.D., Yang A.J., Margol L., Garzon-Rodriguez W., Glabe C.G., and Tenner A.J. Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp. Neurol. 161 (2000) 127-138
134. Whitson J.S., Selkoe D.J., and Cotman C.W. Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science 243 (1989) 1488-1490
135. Wilcock D.M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K.E., Gordon M.N., and Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23 (2003) 3745-3751
136. Wilcock D.M., Munireddy S.K., Rosenthal A., Ugen K.E., Gordon M.N., and Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol. Dis. 15 (2004) 11-20
137. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., and Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 1 (2004) 24
138. Wyss-Coray T., Yan F., Lin A.H., Lambris J.D., Alexander J.J., Quigg R.J., and Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 10837-10842
139. Yankner B.A., Dawes L.R., Fisher S., Villa K.L., Oster G.M.L., and Neve R.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245 (1989) 417-420
140. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., and Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 16168-16173
141. Zaiss A.K., and Muruve D.A. Immune responses to adeno-associated virus vectors. Curr. Gene Ther. 5 (2005) 323-331
142. Zlokovic B.V. Clearing amyloid through the blood-brain barrier. J. Neurochem. 89 (2004) 807-811
143. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28 (2005) 202-208